|
US3152148A
(en)
|
1963-01-03 |
1964-10-06 |
Dow Chemical Co |
Preparation of comenic and pyromeconic acids
|
|
US3441605A
(en)
|
1965-02-17 |
1969-04-29 |
Wallace & Tiernan Inc |
Diketo-dicarboxylic acids and salts and preparation thereof by alkaline oxidation
|
|
GB1196597A
(en)
|
1966-12-21 |
1970-07-01 |
Geigy Uk Ltd |
Preparation of an Oxido-Cyclodecene
|
|
GB1196598A
(en)
|
1966-12-21 |
1970-07-01 |
Geigy Uk Ltd |
Preparation of a Ketosebacic Acid
|
|
FR1545224A
(fr)
|
1966-12-21 |
1968-11-08 |
Geigy Ag J R |
Procédé de préparation de l'acide sébacique
|
|
GB1196596A
(en)
|
1966-12-21 |
1970-07-01 |
Geigy Uk Ltd |
Preparation of a hydroxysebacic acid
|
|
GB1196594A
(en)
|
1966-12-21 |
1970-07-01 |
Geigy Uk Ltd |
Improvements in and relating to the production of Sebacic Acid
|
|
GB1196595A
(en)
|
1966-12-21 |
1970-07-01 |
Geigy Uk Ltd |
Preparation of a Lactone
|
|
US3773946A
(en)
|
1969-09-02 |
1973-11-20 |
Parke Davis & Co |
Triglyceride-lowering compositions and methods
|
|
US3930024A
(en)
|
1969-09-02 |
1975-12-30 |
Parke Davis & Co |
Pharmaceutical compositions and methods
|
|
JPS5522636A
(en)
|
1978-08-04 |
1980-02-18 |
Takeda Chem Ind Ltd |
Thiazoliding derivative
|
|
US4281200A
(en)
|
1979-08-30 |
1981-07-28 |
The Dow Chemical Company |
Catalytic process for converting oxazolidinones to their corresponding aminoalcohols
|
|
JPS5639033A
(en)
|
1979-09-04 |
1981-04-14 |
Kao Corp |
Alpha-mono(methyl-branched alkyl glyceryl ether and skin cosmetic containing the same
|
|
IL64542A0
(en)
|
1981-12-15 |
1982-03-31 |
Yissum Res Dev Co |
Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
|
|
IT1164254B
(it)
|
1983-05-30 |
1987-04-08 |
Luso Farmaco Inst |
3-(3-idrossibutossi)-1-butanolo e suo metodo di preparazione
|
|
JPS59232811A
(ja)
|
1983-06-16 |
1984-12-27 |
Sumitomo Chem Co Ltd |
芳香族ポリアミドイミド樹脂成形体の製造方法
|
|
JPS60136512A
(ja)
|
1983-12-26 |
1985-07-20 |
Eisai Co Ltd |
脂質代謝改善剤
|
|
DE3423166A1
(de)
|
1984-06-22 |
1986-01-02 |
Epis S.A., Zug |
Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
|
|
US4896344A
(en)
|
1984-10-15 |
1990-01-23 |
Grady John K |
X-ray video system
|
|
US4634119A
(en)
|
1985-07-11 |
1987-01-06 |
Pesthy Paul K |
Resilient exercise machine with body support platform
|
|
US4714762A
(en)
|
1986-10-31 |
1987-12-22 |
Warner-Lambert Company |
Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
|
|
US5166174A
(en)
|
1987-01-28 |
1992-11-24 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Prostaglandins E and anti-ulcers containing same
|
|
US5225439A
(en)
|
1987-01-28 |
1993-07-06 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Prostaglandins E and anti ulcers containing same
|
|
US5428062A
(en)
|
1987-01-28 |
1995-06-27 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Prostaglandins E and anti ulcers containing same
|
|
US4758880A
(en)
|
1987-03-27 |
1988-07-19 |
The Grass Valley Group, Inc. |
Video matte generator
|
|
JP2999579B2
(ja)
|
1990-07-18 |
2000-01-17 |
武田薬品工業株式会社 |
Ｄｎａおよびその用途
|
|
US5254589A
(en)
|
1991-10-15 |
1993-10-19 |
Warner-Lambert Company |
Sulfonyl urea and carbamate ACAT inhibitors
|
|
IL109431A
(en)
|
1993-05-14 |
2001-01-11 |
Warner Lambert Co |
Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
|
|
US5420339A
(en)
|
1993-11-22 |
1995-05-30 |
Warner-Lambert Company |
Alpha-aryl or heteroaryl-substituted amide ester ACAT inhibitors
|
|
JP2937012B2
(ja)
|
1994-04-08 |
1999-08-23 |
時久 増田 |
角筒包装袋の製造方法及び装置
|
|
US5578639A
(en)
|
1994-07-01 |
1996-11-26 |
Warner-Lambert Company |
PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
|
|
US5504073A
(en)
|
1994-07-01 |
1996-04-02 |
Warner-Lambert Company |
PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
|
|
SE9500778D0
(sv)
|
1995-03-03 |
1995-03-03 |
Pharmacia Ab |
Process for producing a protein
|
|
US5648387A
(en)
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
AU720853B2
(en)
|
1995-11-02 |
2000-06-15 |
Warner-Lambert Company |
Method and pharmaceutical composition for regulating lipid concentration
|
|
JP4139448B2
(ja)
|
1996-08-13 |
2008-08-27 |
信越化学工業株式会社 |
α−ブロモ，ω−クロロアルカンの製造方法
|
|
US5807846A
(en)
|
1996-11-14 |
1998-09-15 |
Warner-Lambert Company |
Phosphonamide ACAT inhibitors
|
|
IL119971A
(en)
|
1997-01-07 |
2003-02-12 |
Yissum Res Dev Co |
Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
|
|
US6093744A
(en)
|
1997-04-21 |
2000-07-25 |
Warner-Lambert Company |
N-acyl sulfamic acid esters useful as hypocholesterolemic agents
|
|
IL121165A0
(en)
|
1997-06-26 |
1997-11-20 |
Yissum Res Dev Co |
Pharmaceutical compositions containing carboxylic acids and derivatives thereof
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
PL341397A1
(en)
|
1997-11-25 |
2001-04-09 |
Warner Lambert Co |
Inhibition of lipoprotein oxidation
|
|
US6410802B1
(en)
|
1999-04-01 |
2002-06-25 |
Esperion Therapeutics, Inc. |
Methods for synthesizing ether compounds and intermediates therefor
|
|
JP2004531459A
(ja)
|
2000-10-11 |
2004-10-14 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
|
|
CN101426763A
(zh)
|
2000-10-11 |
2009-05-06 |
埃斯佩里安医疗公司 |
用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
|
|
US7304093B2
(en)
|
2000-10-11 |
2007-12-04 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
CN1894195A
(zh)
|
2000-10-11 |
2007-01-10 |
埃斯佩里安医疗公司 |
用于控制胆固醇以及相关用途的醚化合物以及组合物
|
|
CA2425311C
(en)
|
2000-10-11 |
2011-06-14 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
US7053046B2
(en)
|
2001-12-21 |
2006-05-30 |
Mcgrath Kevin |
Peptide activators of VEGF
|
|
ES2625429T3
(es)
|
2003-01-23 |
2017-07-19 |
Esperion Therapeutics Inc. |
Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
|
|
JP2007525408A
(ja)
|
2003-12-24 |
2007-09-06 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロール管理および関連使用のためのケトン化合物および組成物
|
|
JP4553181B2
(ja)
|
2004-03-25 |
2010-09-29 |
株式会社サタケ |
残留農薬分析方法
|
|
US8209479B2
(en)
|
2007-07-18 |
2012-06-26 |
Google Inc. |
Memory circuit system and method
|
|
MX367352B
(es)
|
2012-01-06 |
2019-08-16 |
Gemphire Therapeutics Inc |
Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
|
|
US9662307B2
(en)
*
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US20160058751A1
(en)
|
2013-03-28 |
2016-03-03 |
Cellworks Group, Inc. |
Composition and method for treating cancer
|
|
WO2015018060A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Agios Pharmaceuticals, Inc. |
Crystalline forms of therapeutically active compounds and use thereof
|
|
EP3267989A4
(en)
|
2015-03-13 |
2018-11-07 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
WO2017023165A1
(en)
|
2015-08-04 |
2017-02-09 |
Dezima Pharma B.V. |
Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
|
|
WO2018148417A1
(en)
|
2017-02-08 |
2018-08-16 |
Esperion Therapeutics, Inc. |
Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
|
|
TW201906599A
(zh)
|
2017-05-11 |
2019-02-16 |
美商珍費爾醫療公司 |
吉卡賓組成物及其使用方法
|
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
|
CN107628975B
(zh)
*
|
2017-09-17 |
2019-10-29 |
贵州医科大学 |
赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
|
|
CN109721486A
(zh)
*
|
2017-10-31 |
2019-05-07 |
鲁南制药集团股份有限公司 |
一种8-羟基-2,2,14,14-四甲基-十五烷二酸的合成方法
|
|
AU2019221765A1
(en)
|
2018-02-16 |
2020-09-10 |
Esperion Therapeutics, Inc. |
Sustained release formulations of bempedoic acid
|
|
EP3666750A1
(en)
*
|
2018-12-10 |
2020-06-17 |
Sandoz AG |
Crystalline form of bempedoic acid
|
|
CA3125384A1
(en)
|
2018-12-31 |
2020-07-09 |
Lupin Limited |
Novel salts and polymorphic form of bempedoic acid
|
|
MX2021015936A
(es)
|
2019-06-21 |
2022-04-26 |
Esperion Therapeutics Inc |
Metodos para preparar acido bempedoico y composiciones del mismo.
|
|
US12516013B2
(en)
*
|
2019-12-06 |
2026-01-06 |
Synthon B.V. |
Crystalline forms of sodium salt of Bempedoic acid
|
|
WO2022149161A1
(en)
|
2021-01-05 |
2022-07-14 |
Dr. Reddy's Laboratories Limited |
Process for preparation of bempedoic acid and its intermediates
|